Login
$ANEB
$0.36 +$0.00 (0.0%) Close

Company Executives

Management Team

From Forms 3, 4 and 5 filed in the last 18 months
Officer Age In this role Joined 2024 pay Source
Richard Anthony Cunningham Also a director
Chief Executive Officer
54 Not stated Not stated $1,700,210

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
8
serving now
Independent
5 of 6
stated in the proxy; 2 not stated
Average tenure
3.6 years
from year joined
CEO also chairs the board
No
Joseph F. Lawler
Director Age On board Independent Committees Other public boards 2024 pay Source
Joseph F. Lawler
52 2020
5 years
Independent None stated None stated $83,106
Richard Anthony Cunningham
54 2023
2 years
Not independent None stated None stated Paid as CEO
Aron R. English
42 2020
5 years
Not stated None stated None stated $66,873
Areta Kupchyk
67 2021
4 years
Independent None stated None stated $76,873
Nathaniel Calloway
42 2022
3 years
Not stated None stated None stated $67,263
Kenneth Lin
51 2021
4 years
Independent
Audit Compensation
None stated $68,236
Jason M. Aryeh
56 2021
4 years
Independent
Audit
Ligand Pharmaceuticals Inc. $83,236
Bimal Shah
48 2023
2 years
Independent
Audit · Chair
None stated $124,531

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

6 disclosed in the proxy filed Mar 6, 2025
22NW
Approximately $10 million
December 2024

December 2024 private placement: 10,101,010 shares of Common Stock sold to 22NW at $0.99 per share, about $10 million

22NW
Amount not stated
February 2025

Lock-Up Agreement entered into with 22NW

22NW
Amount not stated
November 13, 2023

Loan and Security Agreement under which the Company issued 300,000 shares of Common Stock to 22NW upon signing

With 22NW, LP and JFL Capital Management LLC Open in proxy
22NW
$3 million
February 10, 2025

Amended and Restated Loan Agreement reducing maximum loan advance to $3 million and assigning 22NW, LP's rights to 22NW

With 22NW, LP Open in proxy
Joseph F. Lawler, M.D., Ph.D.
Founder and a member of our Board of Directors; founder and Managing Member of JFL
Amount not stated

JFL Capital Management LLC is a party to the Loan and Security Agreement with 22NW, LP

22NW
Approximately $5.0 million
September 2022

September 2022 private placement: 1,703,577 Units purchased by 22NW at $2.935 per Unit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support